Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause Maternal exposure timing unspecified? 114 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 114 reports of Maternal exposure timing unspecified have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 0.2% of all adverse event reports for OMALIZUMAB.

114
Reports of Maternal exposure timing unspecified with OMALIZUMAB
0.2%
of all OMALIZUMAB reports
1
Deaths
19
Hospitalizations

How Dangerous Is Maternal exposure timing unspecified From OMALIZUMAB?

Of the 114 reports, 1 (0.9%) resulted in death, 19 (16.7%) required hospitalization, and 2 (1.8%) were considered life-threatening.

Is Maternal exposure timing unspecified Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMALIZUMAB. However, 114 reports have been filed with the FAERS database.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause Maternal exposure timing unspecified?

RITUXIMAB (402) METHOTREXATE (350) ADALIMUMAB (343) DICLOFENAC (331) TOCILIZUMAB (327) HYDROXYCHLOROQUINE (309) FOLIC ACID (304) INFLIXIMAB (303) LEFLUNOMIDE (302) SECUKINUMAB (301)

Which OMALIZUMAB Alternatives Have Lower Maternal exposure timing unspecified Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All Maternal exposure timing unspecified Reports All Drugs Causing Maternal exposure timing unspecified OMALIZUMAB Demographics